83 related articles for article (PubMed ID: 22773738)
1. Novel fragments of clavulanate observed in the structure of the class A β-lactamase from Bacillus licheniformis BS3.
Power P; Mercuri P; Herman R; Kerff F; Gutkind G; Dive G; Galleni M; Charlier P; Sauvage E
J Antimicrob Chemother; 2012 Oct; 67(10):2379-87. PubMed ID: 22773738
[TBL] [Abstract][Full Text] [Related]
2. Structure of the covalent adduct formed between Mycobacterium tuberculosis beta-lactamase and clavulanate.
Tremblay LW; Hugonnet JE; Blanchard JS
Biochemistry; 2008 May; 47(19):5312-6. PubMed ID: 18422342
[TBL] [Abstract][Full Text] [Related]
3. Overcoming resistance to beta-lactamase inhibitors: comparing sulbactam to novel inhibitors against clavulanate resistant SHV enzymes with substitutions at Ambler position 244.
Thomson JM; Distler AM; Bonomo RA
Biochemistry; 2007 Oct; 46(40):11361-8. PubMed ID: 17848099
[TBL] [Abstract][Full Text] [Related]
4. X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 beta-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid.
Swarén P; Golemi D; Cabantous S; Bulychev A; Maveyraud L; Mobashery S; Samama JP
Biochemistry; 1999 Jul; 38(30):9570-6. PubMed ID: 10423234
[TBL] [Abstract][Full Text] [Related]
5. Different intermediate populations formed by tazobactam, sulbactam, and clavulanate reacting with SHV-1 beta-lactamases: Raman crystallographic evidence.
Kalp M; Totir MA; Buynak JD; Carey PR
J Am Chem Soc; 2009 Feb; 131(6):2338-47. PubMed ID: 19161282
[TBL] [Abstract][Full Text] [Related]
6. Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallography.
Helfand MS; Totir MA; Carey MP; Hujer AM; Bonomo RA; Carey PR
Biochemistry; 2003 Nov; 42(46):13386-92. PubMed ID: 14621983
[TBL] [Abstract][Full Text] [Related]
7. Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitors.
Helfand MS; Taracila MA; Totir MA; Bonomo RA; Buynak JD; van den Akker F; Carey PR
Biochemistry; 2007 Jul; 46(29):8689-99. PubMed ID: 17595114
[TBL] [Abstract][Full Text] [Related]
8. Crystal structures of the Bacillus licheniformis BS3 class A beta-lactamase and of the acyl-enzyme adduct formed with cefoxitin.
Fonzé E; Vanhove M; Dive G; Sauvage E; Frère JM; Charlier P
Biochemistry; 2002 Feb; 41(6):1877-85. PubMed ID: 11827533
[TBL] [Abstract][Full Text] [Related]
9. Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamase.
Totir MA; Helfand MS; Carey MP; Sheri A; Buynak JD; Bonomo RA; Carey PR
Biochemistry; 2007 Aug; 46(31):8980-7. PubMed ID: 17630699
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of class A and class C beta-lactamases by penems: crystallographic structures of a novel 1,4-thiazepine intermediate.
Nukaga M; Abe T; Venkatesan AM; Mansour TS; Bonomo RA; Knox JR
Biochemistry; 2003 Nov; 42(45):13152-9. PubMed ID: 14609325
[TBL] [Abstract][Full Text] [Related]
11. Tazobactam forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV-1 beta-lactamase: 1.63 A crystal structure.
Padayatti PS; Helfand MS; Totir MA; Carey MP; Hujer AM; Carey PR; Bonomo RA; van den Akker F
Biochemistry; 2004 Feb; 43(4):843-8. PubMed ID: 14744126
[TBL] [Abstract][Full Text] [Related]
12. New Conformations of Acylation Adducts of Inhibitors of β-Lactamase from Mycobacterium tuberculosis.
Tassoni R; Blok A; Pannu NS; Ubbink M
Biochemistry; 2019 Feb; 58(7):997-1009. PubMed ID: 30632739
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of TEM-2 beta-lactamase from Escherichia coli by clavulanic acid: observation of intermediates by electrospray ionization mass spectrometry.
Brown RP; Aplin RT; Schofield CJ
Biochemistry; 1996 Sep; 35(38):12421-32. PubMed ID: 8823177
[TBL] [Abstract][Full Text] [Related]
14. High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 {beta}-lactamase.
Padayatti PS; Helfand MS; Totir MA; Carey MP; Carey PR; Bonomo RA; van den Akker F
J Biol Chem; 2005 Oct; 280(41):34900-7. PubMed ID: 16055923
[TBL] [Abstract][Full Text] [Related]
15. Inhibitor-resistant class A beta-lactamases: consequences of the Ser130-to-Gly mutation seen in Apo and tazobactam structures of the SHV-1 variant.
Sun T; Bethel CR; Bonomo RA; Knox JR
Biochemistry; 2004 Nov; 43(44):14111-7. PubMed ID: 15518561
[TBL] [Abstract][Full Text] [Related]
16. Computational modeling study on formation of acyclic clavulanate intermediates in inhibition of class A beta-lactamase: water-assisted proton transfer.
Li R; Feng D; Feng S
J Phys Chem A; 2009 Feb; 113(8):1608-13. PubMed ID: 19191527
[TBL] [Abstract][Full Text] [Related]
17. Why clinically used tazobactam and sulbactam are poor inhibitors of OXA-10 beta-lactamase: Raman crystallographic evidence.
Totir MA; Cha J; Ishiwata A; Wang B; Sheri A; Anderson VE; Buynak J; Mobashery S; Carey PR
Biochemistry; 2008 Apr; 47(13):4094-101. PubMed ID: 18324783
[TBL] [Abstract][Full Text] [Related]
18. The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV beta-lactamase: a study of ambler position Asn276.
Drawz SM; Bethel CR; Hujer KM; Hurless KN; Distler AM; Caselli E; Prati F; Bonomo RA
Biochemistry; 2009 Jun; 48(21):4557-66. PubMed ID: 19351161
[TBL] [Abstract][Full Text] [Related]
19. Hydrolysis of clavulanate by Mycobacterium tuberculosis β-lactamase BlaC harboring a canonical SDN motif.
Soroka D; Li de la Sierra-Gallay I; Dubée V; Triboulet S; van Tilbeurgh H; Compain F; Ballell L; Barros D; Mainardi JL; Hugonnet JE; Arthur M
Antimicrob Agents Chemother; 2015 Sep; 59(9):5714-20. PubMed ID: 26149997
[TBL] [Abstract][Full Text] [Related]
20. Role of the omega-loop in the activity, substrate specificity, and structure of class A beta-lactamase.
Banerjee S; Pieper U; Kapadia G; Pannell LK; Herzberg O
Biochemistry; 1998 Mar; 37(10):3286-96. PubMed ID: 9521648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
